Related Experiment Video
Updated: Oct 13, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Treatment of fungal infections in neutropenic children
T Lehrnbecher1, A H Groll, S J Chanock
1Immunocompromised Host Section, National Cancer Institutes of Health, Bethesda, MD 20892, USA.
Abstract:
Fungal infections have emerged as one of the most significant complications of antineoplastic therapy and marrow transplantation in children. Morbidity and mortality associated with fungal infections are high. Recent trends indicate that the incidence and spectrum of fungal infections are increasing, partly because of the increase in the number of children receiving intensive chemotherapy and marrow transplantation, but also because of the successful management of bacterial and viral infections. Though many factors may contribute to risk for developing a fungal infection, prolonged neutropenia is the most important. Until recently, options for antifungal therapy were limited. Advances include less toxic formulations of amphotericin B and an expanding armamentarium of azoles as well as new antifungal compounds. This review addresses the therapeutic options available for treatment of fungal infections in immunocompromised children.
Insights
Fungal infections are a major risk for children undergoing cancer treatment and marrow transplants. This review covers new antifungal therapies for these immunocompromised children.
Area of Science:
- Pediatric Oncology
- Infectious Diseases
- Hematology
Background:
- Fungal infections are a significant complication in pediatric patients undergoing antineoplastic therapy and marrow transplantation.
- High morbidity and mortality rates are associated with these infections.
- Increasing incidence and spectrum of fungal infections are observed due to intensive treatments and improved management of other infections.
Purpose of the Study:
- To review the therapeutic options for treating fungal infections in immunocompromised children.
- To highlight recent advances in antifungal therapies.
Main Methods:
- Literature review of antifungal therapies for immunocompromised children.
- Discussion of risk factors, including prolonged neutropenia.
- Overview of current and emerging antifungal agents.
Main Results:
- Prolonged neutropenia is the primary risk factor for fungal infections.
- Limited therapeutic options previously existed.
- Advances include less toxic amphotericin B formulations, new azoles, and novel antifungal compounds.
Conclusions:
- Effective management of fungal infections in immunocompromised children requires awareness of risk factors and available therapeutic options.
- Recent advances have expanded the armamentarium for treating these serious infections.
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management
Fungal Phylum Microsporidia
Cryptococcal Meningitis

